raloxifene hydrochloride has been researched along with 9,10-dimethyl-1,2-benzanthracene in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, DR; Black, LJ; Clemens, JA; Jones, CD | 1 |
| Jordan, VC | 1 |
| Black, LJ; Clemens, JA; Falcone, JF; Jevnikar, MG; Jones, CD; Peters, MK; Pike, AJ; Thompson, AR | 1 |
| Cockcroft, N; Dahllund, J; Härkönen, P; Hemminki, K; Kangas, L; Koskinen, M; Laine, A; Peng, Z; Qu, Q; Väänänen, K; Zheng, H | 1 |
| Amari, G; Armani, E; Caruso, PL; Civelli, M; Delcanale, M; Galbiati, E; Ghirardi, S | 1 |
| Aoyagi, Y; Asao, T; Buzdar, AU; Hashimoto, A; Sato, K; Shibata, J; Terada, T; Wierzba, K; Yamamoto, Y; Yano, S; Yonekura, K | 1 |
| Beckett, LA; Degregorio, MW; Gregg, JP; Marchisano-Karpman, C; Read, KC; Wurz, GT; Yu, Q | 1 |
| Laxmi, YR; Liu, X; Okamoto, K; Okamoto, Y; Sekimoto, M; Shibutani, S; Suzuki, N | 1 |
| Frye, CA; Walf, AA | 1 |
| Jamdade, VS; Kumar, P; Lahkar, M; Mundhe, NA; Tadla, V | 1 |
| Elkhoely, AA; Kabel, AM | 1 |
| Ilhan, N; Ozercan, IH; Susam, S; Tatar, O | 1 |
1 review(s) available for raloxifene hydrochloride and 9,10-dimethyl-1,2-benzanthracene
| Article | Year |
|---|---|
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Mammary Neoplasms, Experimental; Models, Biological; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Thiophenes | 1983 |
11 other study(ies) available for raloxifene hydrochloride and 9,10-dimethyl-1,2-benzanthracene
| Article | Year |
|---|---|
Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Castration; Drug Evaluation, Preclinical; Estradiol; Estrogen Antagonists; Female; Luteinizing Hormone; Mammary Neoplasms, Experimental; Piperidines; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Tamoxifen | 1983 |
Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effec
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Estrogen Antagonists; Female; Mammary Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Structure-Activity Relationship; Uterus | 1984 |
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bone and Bones; Breast Neoplasms; Cholesterol; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organ Size; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reference Values; Tamoxifen; Toremifene; Transplantation, Heterologous; Tumor Cells, Cultured; Uterus | 2000 |
Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Benzopyrans; Bone Density; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Molecular Structure; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Uterus | 2002 |
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Carcinogens; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Humans; Luciferases; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Ovary; Protein Binding; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tamoxifen; Time Factors; Transcriptional Activation; Treatment Outcome; Uterus | 2005 |
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Carcinoma; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred SENCAR; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Antineoplastic Agents, Hormonal; Biological Availability; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor Modulators; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organophosphates; Phosphorylation; Prodrugs; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Transplantation, Heterologous | 2008 |
Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anxiety; Behavior, Animal; Carcinogens; Cell Proliferation; Depression; Disease Models, Animal; Drug Interactions; Estradiol; Estrogens; Female; Maze Learning; Neoplasms; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Long-Evans; Regression Analysis; Sexual Behavior, Animal; Swimming; Time Factors; Uterus | 2010 |
Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Cisplatin; Drug Synergism; Female; Inflammation; Kidney Diseases; Mammary Neoplasms, Animal; NF-kappa B; Raloxifene Hydrochloride; Rats; Rats, Wistar; Signal Transduction | 2016 |
Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalase; Fluoxetine; Humans; Interleukin-6; Malondialdehyde; Raloxifene Hydrochloride; Rats; Superoxide Dismutase; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2016 |
Is there any potential anticancer effect of raloxifene and fluoxetine on DMBA-induced rat breast cancer?
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Carcinogens; Enzyme-Linked Immunosorbent Assay; Female; Fluoxetine; Mammary Neoplasms, Experimental; Raloxifene Hydrochloride; Rats; Rats, Wistar; Weight Gain | 2019 |